Resources
128 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 11/24/2021 (updated 3/26/2024)
This webinar will provide participants with an understanding of the role of the medical examiners and coroners in the surveillance of drug overdose deaths, as well as the current efforts to strengthen the death investigation system. The webinar will also cover an overview of the overdose fatality review process and tools available for implementation.
Posted 1/5/2022 (updated 3/26/2024)
This brief reviews the history, harms, pathways and trends that treat children as if they were adults
Posted 7/28/2023 (updated 3/26/2024)
The toolkit Stimulant Safety: Getting Amped Up to Reduce Harms When Using Stimulants was developed through the CDC-funded National Harm Reduction Technical Assistance Center in collaboration with the NASTAD Drug User Health team and consultants. This resource provides education on the reasons people take stimulants, how to minimize harm, reduce stigma around stimulants, support peoples' positive experiences, the intersection of stimulant use and sexual safety, and much more.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 3/2/2022 (updated 3/26/2024)
In this webinar you will hear from Fair Chance employers and advocates. They will offer insights into the benefits of fair chance employment (for formerly incarcerated or otherwise justice impacted people) and outline opportunities to take steps toward becoming a Fair Chance employer.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 3/3/2022 (updated 3/26/2024)
Drug overdose is a nationwide epidemic that claimed the lives of over 100,000 people in the United States in the past year. Opioids, either alone or in combination with other drugs or alcohol, were responsible for approximately 70 percent of these deaths. Many of those 70,000 people would be alive today if they had been administered the opioid antagonist naloxone and, where needed, other emergency care.
Posted 9/8/2023 (updated 3/27/2024)
With a large number of individuals incarcerated in the United States, there is a growing problem with the effects it can have on a person's health. The National Institute for Health Care Management (NIHCM) has provided an infographic detailing the effects, health conditions, and growing inequality people live with while incarcerated.
Posted 3/9/2022 (updated 3/27/2024)
A disproportionate number of people in jails have substance use disorders (SUDs).1 Incarceration provides a valuable opportunity for identifying SUD and addressing withdrawal.* Within the first few hours and days of detainment, individuals who have suddenly stopped using alcohol, opioids, or other drugs may experience withdrawal symptoms, particularly when they have used the substances heavily or long-term. Without its identification and timely subsequent medical attention, withdrawal can lead to serious injury or death. Deaths from withdrawal are preventable, and jail administrators have a pressing responsibility to establish and implement withdrawal policy and protocols that will save lives and ensure legal compliance. This brief describes the scope of the challenge, provides an overview of constitutional rights and key legislation related to substance use withdrawal, and outlines steps for creating a comprehensive response to SUD.